Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) have received an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $25.35.
KURA has been the subject of several recent research reports. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Barclays set a $24.00 target price on shares of Kura Oncology in a report on Wednesday, October 14th. UBS Group reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Monday, October 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, October 15th. Finally, Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th.
View Our Latest Stock Report on Kura Oncology
Kura Oncology Trading Up 6.9%
NASDAQ KURA opened at $7.27 on Thursday. Kura Oncology has a 1-year low of $6.75 and a 1-year high of $13.90. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. The stock has a 50-day moving average of $10.70 and a 200-day moving average of $9.79. The firm has a market cap of $646.74 million, a PE ratio of -2.16 and a beta of 0.56.
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. As a group, sell-side analysts forecast that Kura Oncology will post -3.25 EPS for the current year.
Insiders Place Their Bets
In other Kura Oncology news, COO Kathleen Ford sold 3,668 shares of the business’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $39,431.00. Following the transaction, the chief operating officer owned 142,986 shares in the company, valued at approximately $1,537,099.50. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 28,802 shares of the business’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total transaction of $309,621.50. Following the completion of the transaction, the insider owned 141,095 shares in the company, valued at $1,516,771.25. The trade was a 16.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 153,881 shares of company stock worth $1,708,183. 7.60% of the stock is currently owned by insiders.
Institutional Trading of Kura Oncology
Large investors have recently modified their holdings of the business. IFP Advisors Inc raised its holdings in Kura Oncology by 136.5% in the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after acquiring an additional 1,467 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Kura Oncology by 14.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,232 shares of the company’s stock valued at $175,000 after acquiring an additional 2,104 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Kura Oncology by 11.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock valued at $194,000 after acquiring an additional 2,304 shares in the last quarter. Sterling Capital Management LLC lifted its position in Kura Oncology by 842.5% in the 3rd quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock valued at $30,000 after acquiring an additional 2,519 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in Kura Oncology by 22.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company’s stock valued at $154,000 after purchasing an additional 2,656 shares during the last quarter.
Kura Oncology Company Profile
Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.
Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.
Featured Stories
- Five stocks we like better than Kura Oncology
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
